Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic

Isabel Bergeri1 | Hannah C. Lewis1 | Lorenzo Subissi1 | Anthony Nardone1,2 | Marta Valenciano1,2 | Brianna Cheng1 | Ketevan Glonti1 | Bridget Williams1 | Ibukun-Oluwa Omolade Abejirinde1 | Alice Simniceanu1 | Alessandro Cassini1 | Rebecca Grant1 | Angel Rodriguez3 | Andrea Vicari3 | Lubna Al Ariqi4 | Tasnim Azim5 | Pushpa Ranjan Wijesinghe5 | Soatiana Cathycia Rajatonirina6 | Joseph Chukwudi Okeibunor6 | Linh-Vi Le7 | Mark Katz8 | Aisling Vaughan8 | Pernille Jorgensen8 | Gudrun Freidl8 | Richard Pebody8 | Maria D. Van Kerkhove1

Background: The declaration of Coronavirus disease 2019 (COVID-19) as a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 required rapid implementation of early investigations to inform appropriate national and global public health actions.

Methods: The suite of existing pandemic preparedness generic epidemiological early investigation protocols was rapidly adapted for COVID-19, branded the ‘UNITY studies’ and promoted globally for the implementation of standardized and quality studies. Ten protocols were developed investigating household (HH) transmission, the first few cases (FFX), population seroprevalence (SEROPREV), health facilities transmission (n = 2), vaccine effectiveness (n = 2), pregnancy outcomes and transmission, school transmission, and surface contamination. Implementation was supported by WHO and its partners globally, with emphasis to support building surveillance and research capacities in low- and middle-income countries (LMIC).

Results: WHO generic protocols were rapidly developed and published on the WHO website, 5/10 protocols within the first 3 months of the response. As of 30 June 2021, 172 investigations were implemented by 97 countries, of which 62 (64%) were LMIC. The majority of countries implemented population...
1 | BACKGROUND

In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for coronavirus disease 2019 (COVID-19), was first identified in Wuhan, China, from where it rapidly spread worldwide. COVID-19 was declared as a public health emergency of international concern (PHEIC) by the World Health Organization (WHO) on 30 January 2020.

One of the key difficulties for decision makers in the early phase of any epidemic of a novel pathogen is to determine the appropriate public health measures in the absence of information on transmission characteristics, extent of infection, severity, and scale of the threat. Following a review of the global response to the last pandemic (2009 influenza pandemic H1N1),1 the global Consortium for the Standardization of Influenza Seroepidemiology (CONSISE)2 and WHO’s Influenza Pandemic Special Investigations and Studies (IPSS) initiative were established to develop a suite of standardized early investigation protocols,3 supported by the Global Influenza Programme4 and the Pandemic Influenza Preparedness (PIP) Framework.5 Standardized protocols were also implemented following the emergence of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in 20126 and Zika virus in 20167 with delineation of a comprehensive global research agenda.8

Building on these global pandemic preparedness efforts, we describe the rapid adaptation and implementation of WHO early investigation protocols for COVID-19, branded the ‘UNITY studies’.9 to generate local data to better inform appropriate national and global public health actions and guidelines. The on-going and future value of such studies for pandemic preparedness and response is discussed.

2 | METHODS

2.1 | Overall concept

UNITY studies enable all countries to rapidly and systematically collect standardized robust data on key epidemiological, virological, and clinical parameters to understand key characteristics of SARS-CoV-2.

2.2 | Embedment into global WHO COVID strategic plan, financing, and accountability

The UNITY initiative is embedded into both 2020 and 2021 WHO’s COVID-19 Strategic Preparedness Response Plans (SPRP) and COVID-19 Monitoring and Evaluation framework.10 Financial support from May 2021 (see acknowledgements) was instrumental for LMIC.

2.3 | Generic protocol development

Ten generic protocols using eight study methodologies were developed (three adapted from available IPSS protocols). These investigate household (HH) transmission, the first few cases (FFX) and their contacts, population seroprevalence (SEROPREV), health facility transmission (two protocols), vaccine effectiveness (two protocols), pregnancy outcomes and transmission, school transmission, and surface contamination. More information on each protocol is described in Table 1.

Four protocols were designed from inception to be multi-country and multi-centre research studies with sharing of anonymised individual level data, a subsequent planned pooled analysis and related tools including joint data platforms (see Table 1). Remaining protocols were mostly considered to be enhanced surveillance protocols by implementing countries.

2.4 | Implementation strategy

WHO Headquarter (HQ), Regional Offices (RO) and Country Offices (CO) and its Special research programmes, supported the dissemination and implementation of protocols to countries, with translation in the six official languages of WHO. This was in interaction with Ministries of Health, local institutions, and through existing collaborations with relevant disease networks and national and international partners (e.g., academic institutions, US-CDC, and Institut Pasteur). Dissemination was also through United Nations and WHO information products and publications including the WHO website and a generic WHO email address. An insignia (Figure 1) was designed to foster belonging to a join global effort.
| Protocols name | Description | Date of first publication of protocol on WHO website | Number of countries implementing study | Number of countries intending to implement study |
|---------------|-------------|---------------------------------------------------|--------------------------------------|---------------------------------|
| First Few X (FFX) cases and contacts transmission | A prospective case-ascertained investigation of all identified close contacts of laboratory-confirmed infections to characterize the transmission dynamics and clinical spectrum of COVID-19 infection in the general population | 31/01/2020 | 24 | 17 (71%) 7 (29%) | 3 |
| Household (HH) transmission | A prospective investigation of household contacts of laboratory-confirmed COVID-19 cases to reinforce the estimates of transmission dynamics and clinical spectrum of infection obtained from the FFX studies for the general population. | 25/01/2020 | 13 | 5 (38%) 8 (62%) | 1 |
| Health facility transmission | Two protocols available to assess the transmissibility of and risk factors for COVID-19 infection among health workers:  
- Case–control study  
- Prospective cohort study | 01/02/2020  
26/05/2020 | 36 | 25 (69%) 11 (31%) | 17 |
| Surface contamination and transmission | A practical “how to” guide on surface sampling for COVID-19 virus to estimate the persistence of contamination on different surfaces and their possible role in onward transmission. | 20/02/2020 | - | - | - |
| Population-based age-stratified seroprevalence (SEROPREV) | Both cross-sectional and longitudinal cohort designs to conduct serological surveys to estimate cumulative incidence in the population by age and sex. | 19/03/2020 | 71 | 50 (70%) 21 (30%) | 27 |
| School transmission | A prospective case-ascertained investigation of school contacts of a laboratory-confirmed case of COVID-19 to understand the dynamics of infection among students and staff of schools and childcare institutions | 30/11/2020 | - | - | - |

(Continues)
2.5 | Comparability of results through standardization and direct country support

WHO offered substantial technical, financial, and material support to national investigation teams to implement quality UNITY studies, particularly in LMIC. Technical support included scientific review of locally adapted protocols, provision of tools including the option of using Go.Data software\(^1\), and guidance for field implementation and quality monitoring, advice on laboratory methods, and assistance with data analysis. Training in scientific writing was provided to national teams to facilitate public dissemination of results.

To enhance the comparability of different studies, WHO also advocated for the standardization of serology laboratory methods. Serology testing was standardized through various means: from March 2021 central WHO procurement of manual total antibody ELISAs targeting the receptor-binding domain (RCB) of SARS-CoV-2 spike (S) protein and that demonstrated sensitivity ≥95% and specificity ≥99% in multiple independent evaluations including also samples from mild and asymptomatic infections\(^1\); provision of research reagent and panel from April 2020\(^2\); comparative performance evaluation of commercially available assays from Dec 2020\(^2\); and availability of International Standard by December 2020\(^3\).

As collaborators undertaking UNITY investigations, national teams were asked to share aggregate results in standardized templates while being assured that ownership of primary data rested firmly with the implementing countries and institutions.

2.6 | Monitoring of country adoption of protocols

WHO ROs and COs provided weekly updates on the number of countries adopting UNITY studies, defined as either ‘intending to undertake’ or ‘having implemented’ a protocol. ‘Implementation’ was defined as a nationally adapted protocol scientifically validated by WHO, national ethical approval obtained (or waived), and initiation of the investigation (i.e., at least one participant enrolled or one sample taken).

3 | RESULTS

Five of the ten protocols were published on the WHO website within the first 3 months of response (before 1 April 2020). As of 30 June
2021, 129 countries registered intention to undertake investigations aligned with WHO UNITY studies, and 172 studies had been implemented by 97 countries of which 64% (62/97) were low- and middle-income countries (LMIC) (Table 1 and Figure 2). Studies have been implemented in all WHO regions and in half (53%, 34/64) of all Humanitarian Response Plan (HRP) countries.15

The most commonly implemented investigation was the SEROPREV investigation, which has been implemented by 71 countries (Table 1), followed by FFX and HH transmission investigations (n = 37), this last one particularly in the early stage of the pandemic. Health facility transmission investigations were implemented in 36 countries. The monitoring of countries which aligned with or adopted the school or surface contamination protocol was not possible with our human resource capacity at that time. Nevertheless, we retrospectively assess that their uptake was likely low for various reasons including the pandemic dynamic. The pregnancy outcomes and transmission protocol and the two vaccine effectiveness protocols were developed and published at later stage, in December 2020 and March 2021, respectively, to respond to emergent scientific priorities, including to measure the performance of newly implemented vaccine programmes. As of 30 June 2021, 39 countries across all six WHO Geographic Regions (most being LMIC) have been supplied by a centrally procured manual ELISA tests to promote standardization of results.

National teams are sharing standardized results in the templates provided. UNITY studies has enabled countries to more accurately estimate epidemiological indicators, such as transmission and severity parameters, risk factors, seroprevalence, cumulative incidence and secondary attack and infection rates, thereby enhancing routine surveillance.

4 | DISCUSSION

The widespread adoption of UNITY protocols across all WHO regions indicates that they have addressed subnational and national needs to collect critical data to support local and regional public health decision-making to prevent and control the pandemic. The quarterly monitoring of the implementation of UNITY investigations as a performance indicator of the COVID-19 SPRP10 further reinforces their significance and impact to also inform global normative work.

WHO rapidly adapted and established the suite of protocols as part of its pandemic preparedness and response planning, which were rapidly adopted by countries. FFX and HH investigations implementation was more relevant for country action early in the pandemic to robustly define key epidemiological and severity parameters of the infection. Nonetheless, the continued collection of such data can provide important insights into the transmission of variants viruses of interest or of concern. It is likely that SEROPREV investigations were of higher priority for countries for rapid policy decision making (and particularly in countries with low testing capacities or weak case-based reporting system) than for other less used protocols (e.g., school transmission and surface contamination). The assessment of uptake of the more recently developed pregnancy and Vaccine Effectiveness protocols will require more time.

**FIGURE 2** Countries that have started implementing at least one sero-epidemiological investigation aligned with WHO UNITY generic protocols, from Jan 2020 to 30 June 2021
The large number of LMIC, including those affected by armed conflict and political instability (HRP countries), that adopted a UNITY protocol is of note and indicates the value of having readily available, generic protocols that can be adapted for various settings. The number of adopted UNITY studies in this analysis is likely to be under-reported as institutions may have employed the publicly available protocols independent of WHO support or knowledge, particularly in HIC.

The first set of significant funding support arrived 4 months after the first protocols publication which hampered timely implementation in LMIC. Tight deadlines for fund expenditure from effective reception (ex: less than 3.5 months) was an issue for such activities. The support provided enabled countries, regardless of economic status, to build on routine surveillance and develop research capacities, to further scientific learning and support evidence-based response decisions at local, national, regional and international level. Laboratory standardization has been key to enable inter-country comparisons. Main lessons learned are described in Box 1.

**Box 1. Lessons learned from the WHO UNITY framework during the COVID-19 pandemic**

Lessons learned:

- Need for a standardized global framework for epidemiological and laboratory investigations, with ready-to-be used, easily adaptable tools, which are adaptable to any resource setting and which can allow inter-country comparisons
- Operational suite of tools supported country enhanced surveillance, the strengthening research capacities independently to resource setting, and in addressing national, regional and global knowledge gaps
- Such framework could be valuable and replicated for any emerging and re-emerging pathogen pandemic readiness and preparedness plans
- Timely and pooled fund availability to ensure equitable support is instrumental in LMIC
- Building on existing networks of partners, research groups, surveillance systems and public health services were essential for the feasibility of such initiatives

An after action review and evaluation of the UNITY initiatives and its protocols to assess their utility to countries in responding to this pandemic and whether they fulfilled key initial objectives started in September 2021 and will be valuable to inform future pandemic preparedness, readiness and response strategy to any respiratory pathogens.

**ACKNOWLEDGEMENTS**

The authors would like to thank people in all countries who are working in the global response effort to COVID-19, to thank all WHO regional and country offices and partners organizations such as Institut Pasteur and the Institut Pasteur International Network, US-CDC, the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), as well as all individuals who supported, conducted or participated in each of the studies supported.

Further acknowledgement to the following WHO staff: Ana Paula Coutinho Rehse, Giorgia Gon, Vicki Indenbaum, Amal Barakat, Eman Aly, Arash Rashidian, Bassim Zahed, Francis Inbanathan, Pushpa Wijesinghe, Belinda Herrig, Pui Shan Chung, Juliana Leite, Joao Toledo, Daniel Felkin, Minal Patel, Sudhir Joshi, Jason Mathiu, Ambrose Talisuna, Nygo Nsenga, Tom Grein, Anna Thorson, and Nathalie Broutet.

This work was supported by the COVID-19 Solidarity Response Fund for WHO and German Federal Ministry of Health (BMG) COVID-19 Research and Development grant for WHO.

**AUTHOR CONTRIBUTIONS**

Isabel Bergeri: Conceptualization; formal analysis; funding acquisition; investigation; methodology; project administration; resources; supervision; visualization. Hannah C. Lewis: Conceptualization; formal analysis; investigation; methodology; project administration; supervision. Lorenzo Subissi: Conceptualization; formal analysis; investigation; methodology; project administration; resources; supervision. Anthony Nardone: Conceptualization; formal analysis; investigation; methodology; supervision. Marta Valenciano: Conceptualization; formal analysis; investigation; methodology; supervision. Brianna Cheng: Investigation; project administration; resources; visualization. Ketevan Gionti: Investigation; project administration; resources; visualization. Bridget Williams: Conceptualization; investigation; project administration; resources; visualization. Omolade Abejirinde: Formal analysis; funding acquisition; investigation; methodology; project administration; resources; supervision. Alice Simnieceanu: Formal analysis; funding acquisition; investigation; methodology; project administration; resources; supervision. Rebecca Grant: Conceptualization; formal analysis; project administration; resources; supervision. Andrea Vicari: Conceptualization; formal analysis; funding acquisition; investigation; methodology; project administration; resources; supervision. Lubna Al Araqi: Conceptualization; formal analysis; funding acquisition; investigation;
methodology; project administration; resources; supervision. Tasnim Azim: Conceptualization; funding acquisition; investigation; project administration; resources; supervision. Pushpa Ranjan Wijesinghe: Funding acquisition; investigation; project administration; supervision. Soatiana Cathcia Rajatonirina: Conceptualization; formal analysis; funding acquisition; investigation; project administration; resources; supervision. Joseph Chukwudi Okeibunor: Funding acquisition; investigation; project administration; resources; supervision. Linh-Vi Le: Formal analysis; funding acquisition; investigation; project administration; resources; supervision. Mark Katz: Formal analysis; investigation; methodology; project administration; supervision. Aisling Vaughan: Formal analysis; investigation; project administration; resources; supervision. Pernille Jorgensen: Formal analysis; investigation; project administration; supervision. Gudrun Freidl: Formal analysis; investigation; project administration; resources; supervision. Richard Pebody: Conceptualization; formal analysis; funding acquisition; investigation; methodology; project administration; supervision. Maria D van Kerkhove: Conceptualization; funding acquisition; methodology; project administration; supervision.

REFERENCES

1. World Health Organisation. (2011). Final report of the IHR Review Committee (as presented to 64th WHA). Retrieved from https://www.who.int/teams/ihr/ihr-review-committees/h1n1
2. Consortium for the Standardization of Influenza Seroepidemiology (CONSISE). (n.d.). Protocols. Retrieved 2021, from CONSISE: https://consise.tghn.org/protocols/
3. World Health Organisation. (n.d.). Pandemic Influenza Special Investigations and Studies (IPSS). Retrieved from https://www.who.int/influenza/surveillance_monitoring/influenza_pandemic_special_investigations/en/
4. World Health Organisation. (n.d.). Global influenza programme. Retrieved from https://www.who.int/influenza/about/en/
5. World Health Organisation. (n.d.). Pandemic influenza preparedness (PIP) framework. Retrieved from https://www.who.int/influenza/PIP/en/
6. World Health Organisation. (n.d.). Middle East respiratory syndrome coronavirus (MERS-CoV)/Technical guidance/Investigation tools. Retrieved 2021, from https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers/technical-guidance/investigation-tools
7. World Health Organisation. (2016). WHO Zika virus research agenda. Support and harmonization of research in countries: Standardized research protocols. Retrieved June 2021, from https://www.who.int/health-topics/zika-virus-disease/publications/who-response
8. Van Kerkhove MD, Reveiz L, Souza JP, Jaenisch T, Carson G, Brouet N. Harmonisation of Zika virus research protocols to address key public health concerns. Lancet Glob Health. 2016 Dec;4(12): e911-e912.
9. World Health Organisation. (n.d.). The unity studies: WHO seroepidemiological investigations protocols. Retrieved from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations
10. World Health Organisation. (2021, June). COVID-19 Strategy and planning. Retrieved from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/strategies-and-plans
11. World Health Organisation. (n.d.). Go.Data: managing complex data in outbreak. Retrieved from https://www.who.int/go-data
12. Weidner L, Gânsdorfer S, Unterweger S, et al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. J Clin Virol. 2020:129:104540.
13. Kristiansen PA, Page M, Bemasconi V, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021, April; 397(10282):1347-1348. Retrieved from. https://www.nibsc.org/products/bm_product_catalogue/detail_page.aspx?catid=20/136
14. World Health Organisation. (n.d.). SARS-CoV-2 antibody detecting assay performance evaluation. Retrieved from https://who.int/news-room/articles-detail/who-sars-cov-2-antibody-detecting-assay-performance-evaluation
15. United Nations Office for the Coordination of Humanitarian Affairs (OCHA). (2020). Global humanitarian response plan for covid-19. Retrieved from https://www.unocha.org/sites/unocha/files/GHRP-COVID19_July_update.pdf

How to cite this article: Bergeri I, Lewis HC, Subissi L, et al. Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic. Influenza Other Respi Viruses. 2022;16 (1):7-13. doi:10.1111/irv.12915

PEER REVIEW
The peer review history for this article is available at https://publons.com/publon/10.1111/irv.12915.

ORCID
Isabel Bergeri https://orcid.org/0000-0002-1204-1753
Hannah C. Lewis https://orcid.org/0000-0002-1925-3943
Lorenzo Subissi https://orcid.org/0000-0001-5147-575X Anthony Nardone https://orcid.org/0000-0003-1138-0937 Marta Valenciano https://orcid.org/0000-0002-2056-1062 Brianna Cheng https://orcid.org/0000-0003-2004-2251 Ketevan Glonti https://orcid.org/0000-0001-9991-7991 Bridget Williams https://orcid.org/0000-0002-9677-8305 Ibukun-Oluwa Omolade Abegirin https://orcid.org/0000-0003-0139-0541 Alice Sinniceau https://orcid.org/0000-0003-4068-6177 Rebecca Grant https://orcid.org/0000-0001-8412-8113 Angel Rodriguez https://orcid.org/0000-0002-0061-7567 Andrea Vicari https://orcid.org/0000-0001-5528-2517 Lubna Al Ariqi https://orcid.org/0000-0002-3343-6359 Tasnim Azim https://orcid.org/0000-0003-4127-5871 Pushpa Ranjan Wijesinghe https://orcid.org/0000-0002-7875-0165 Soatiana Cathcia Rajatonirina https://orcid.org/0000-0002-5869-5090 Joseph Chukwudi Okeibunor https://orcid.org/0000-0002-6696-8503 Linh-Vi Le https://orcid.org/0000-0002-5816-7589 Mark Katz https://orcid.org/0000-0002-5532-7276 Aisling Vaughan https://orcid.org/0000-0002-5966-2303 Pernille Jorgensen https://orcid.org/0000-0001-5967-0998 Gudrun Freidl https://orcid.org/0000-0003-0702-0189 Richard Pebody https://orcid.org/0000-0002-9069-2885 Maria D. Van Kerkhove https://orcid.org/0000-0002-6135-0018